GlucoTrack, Inc. Common Stock

Day range

$0.78 – $1.52

Open

$0.84

Prev close

$0.81

Volume

12.86M

Market cap

$477.44K

Shares out

2.37M

P/E

—

P/S

—

P/B

-0.27

P/FCF

—

ROE

915.8%

ROA

-1066.5%

Debt/Equity

-0.14

Div yield

0.00%

As of Oct 23, 2026

• Private placementOct 22, 2026

  On October 22, 2026, Glucotrack, Inc. entered into a securities purchase agreement with certain investors, pursuant to which the Company issued senior secured convertible promissory notes in the aggregate principal amount of $2,564,102.65 for an aggregate cash purchase price of $2,000,000. The Notes, Warrants and related securities were issued in reliance upon the exemption from registration afforded by Section 4(a)(2) of the Securities Act.

• Debt retirementSep 28, 2026

  On September 25, 2026, in connection with the closing of the Company's registered direct offering, the outstanding Bridge Notes were repaid in full.

• Capital allocation updateSep 24, 2026

  The gross proceeds to the Company from the Offering will be approximately $3.1 million, before deducting Placement Agent fees and other offering expenses payable by the Company. The Company expects to use the net proceeds from the Offering to pay off existing debt, with the remainder to be used for working capital and general corporate purposes.

• Director departureSep 18, 2026

  On September 14, 2026, Paul V. Goode notified the Board of Directors of Glucotrack, Inc. (the "Company") of his resignation from the Board, effective immediately.

• Special meeting resultsSep 14, 2026

  On September 11, 2026, the Company held a special meeting of stockholders ... The Company's stockholders approved ... the full issuance of shares of Common Stock ... issuable under the ELOC Purchase Agreement ... to White Lion Capital, LLC.

Days to cover

1.0

Short interest

122.11K

Avg volume

7.39M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• E.F. Hutton & Co. Serves as Exclusive Financial Advisor on Strategic Business Combination Between Glucotrack and Lōkahi Therapeutics and Exclusive Placement Agent for Approximately $5.7 Million Convertible Note Financing
  positiveGlobeNewswire Inc.· Jul 17, 2026
• UPDATE – Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform
  positiveGlobeNewswire Inc.· Jul 16, 2026
• Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
  positiveGlobeNewswire Inc.· May 14, 2026
• Glucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring Technology
  positiveGlobeNewswire Inc.· May 7, 2026
• Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
  positiveGlobeNewswire Inc.· Mar 30, 2026